| 48146-5 |
Myeloperoxidase |
ACnc |
Ser |
Pt |
Qn |
|
|
ACTIVE |
Myeloperoxidase [Units/volume] in Serum |
|
MIN |
DefinitionDescription |
|
|
IU/L |
|
|
|
|
|
|
CHEM |
|
48146-5 |
|
|
|
|
Both |
|
|
|
0 |
Myeloperoxidase Ser-aCnc |
|
|
|
N |
|
Arbitrary concentration; Chemistry; MPO; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR |
2.7 |
2.21 |
|
|
|
|
|
|
|
[IU]/L |
|
|
|
0 |
| 48147-3 |
Oligosaccharides/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Oligosaccharides/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48147-3 |
|
|
|
|
Both |
|
|
|
0 |
Oligosaccharide/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48148-1 |
Observation |
Osmol |
Urine |
Pt |
Qn |
Calculated.Sum of electrolytes |
|
ACTIVE |
Osmolality of Urine by calculated by sum of electrolytes |
|
NAM |
DefinitionDescription |
|
|
mOsm/kg |
|
|
|
|
|
|
CHEM |
|
48148-1 |
|
Calculated.Sum of electrolytes |
|
|
Both |
|
|
|
0 |
Osmolality Ur Calc.Sum of Elec |
|
|
|
N |
|
Calc; Calc.Sum of Elec; Calculation; Chemistry; Kidney; Nephrology; Osmo; Osmolality; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; Urn |
2.79 |
2.21 |
|
|
|
|
|
|
|
mosm/kg |
|
|
Release 2.79: COMPONENT: Improving method; METHOD_TYP: Specifying Calculated; |
0 |
| 48149-9 |
Osmolality.urine/Osmolality.ser |
Ratio |
Urine+Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Osmolality.urine/Osmolality.serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
48149-9 |
|
|
|
|
Both |
|
|
|
0 |
Osmolality Ur/SerPl-Rto |
|
|
|
N |
|
Chemistry; Osmo; Osmol; Osmolality ratio; Osmolality Ur; Osmolality ur:ser; osmolarity; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UA; UR; Ur+SerPl; Urn |
2.44 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4815-7 |
HLA-B17 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-B17 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4815-7 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B17 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48150-7 |
Perseitol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Perseitol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48150-7 |
|
|
|
|
Both |
|
|
|
0 |
Perseitol/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48151-5 |
Sedoheptitol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Sedoheptitol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48151-5 |
|
|
|
|
Both |
|
|
|
0 |
Sedoheptitol/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48152-3 |
Sorbitol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Sorbitol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48152-3 |
|
|
|
|
Both |
|
|
|
0 |
Sorbitol/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48153-1 |
Threitol/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Threitol/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48153-1 |
|
|
|
|
Both |
|
|
|
0 |
Threitol/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48154-9 |
Threo-4,5-Dihydrohexanoate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Threo-4,5-Dihydrohexanoate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48154-9 |
|
|
|
|
Both |
|
|
|
0 |
Threo-4,5-DHA/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; Threo-4,5-DHA; Threo-4,5-dihydrohexanoic acid; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48155-6 |
Threo-4,5-Dihydrohexanolactone/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Threo-4,5-Dihydrohexanolactone/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48155-6 |
|
|
|
|
Both |
|
|
|
0 |
Threo-4,5-DHL/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; Threo-4,5-DHL; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48156-4 |
Threo-4-Deoxytetronate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Threo-4-Deoxytetronate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48156-4 |
|
|
|
|
Both |
|
|
|
0 |
Threo-4-deoxytetronate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48157-2 |
Thymine/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Thymine/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48157-2 |
|
|
|
|
Both |
|
|
|
0 |
Thymine/Creat Ur-sRto |
|
|
|
N |
|
5-Methyluracil; Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48158-0 |
Vanillate/Creatinine |
SRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Vanillate/Creatinine [Molar ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
umol/mmol creatinine |
|
|
|
|
|
|
CHEM |
|
48158-0 |
|
|
|
|
Both |
|
|
|
0 |
Vanillate/Creat Ur-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; Substance concentration ratio; Substance ratio; UA; UCr; UR; Urn; Vanillic acid |
2.7 |
2.21 |
|
|
|
|
|
|
|
umol/mmol{creat} |
|
|
|
0 |
| 48159-8 |
Hepatitis C virus Ab Signal/Cutoff |
RelACnc |
Ser/Plas |
Pt |
Qn |
IA |
|
ACTIVE |
Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
Reference ranges: nonreactive Signal-to-cutoff ratio <1.00__nonreactive If signal-to-cutoff is > or = 1.00 and <8.00: this patient's sample tests reactive with a low s/co ratio: > or = 1.00 and <8.00. The CDC recommends supplemental testing, such as RIBA or nucleic acid amplified testing (NAAT), for confirmation (MMWR no. RR-3, 2003). If NAAT is chosen, please submit a new, frozen plasma or serum specimen. If signal-to-cutoff is > or = 8.00: this patient's sample tests reactive with a high s/co ratio: > or = 8.00. Samples with high s/co ratios have been shown to repeat as positive using a different methodology 95% of the time or greater (CDC MMWR no. RR-3, 2003). Therefore, additional testing for verification of the result is not recommended |
|
|
|
|
|
MICRO |
|
48159-8 |
|
IA |
|
|
Both |
|
|
|
0 |
HCV Ab s/co SerPl IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; co; cut off; EIA; ELFA; ELISA; Enzyme immunoassay; HCV; HCV Ab s/co; HCV Ab Signal; HCVAB; Hep; Hep C; Hepatis; Hepatit; Hepatology; IAA; ID; Infectious Disease; InfectiousDisease; Liver; MEIA; Microbiology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; RlACnc; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; SUDS; UniversalLabOrders |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Changed Order_Obs from Observation Only to fit current order use cases.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4816-5 |
HLA-B18 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-B18 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4816-5 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-B18 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48160-6 |
HTLV I rgp21 Ab |
PrThr |
Ser |
Pt |
Ord |
IB |
|
ACTIVE |
HTLV I rgp21 Ab [Presence] in Serum by Immunoblot |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
48160-6 |
|
IB |
|
|
Both |
|
|
|
0 |
HTLV I rgp21 Ab Ser Ql IB |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Blt; HTLV 1 GD21; Human T-cell Leukemia Virus; Human T-cell Lymphotrophic Virus; ID; IMMUNE BLOT; Immunobl; Immunoblot; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; RIBA; Screen; Serum; SR; WB; WBLOT; West blot; West blt; Western blot |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 48161-4 |
PROS1 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
PROS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
METHOD: THIS TEST IS PERFORMED BY DIRECT MUTATION ANALYSIS OF LEUKOCYTE GENOMIC DNA USING INSTRUMENTATION (LIGHT CYCLER) FROM ROCHE MOLECULAR SYSTEMS. RESULT: Negative EXPECTED VALUES: Negative INTERPRETATION: THIS INDIVIDUAL DOES NOT HAVE THE PROTEIN S S460P (HEERLEN) MUTATION. ALTHOUGH THE PROTEIN S S460P (HEERLEN) MUTATION IS ABSENT, THE INDIVIDUAL MAY HAVE OTHER GENETIC AND ENVIRONMENTAL RISK FACTORS FOR THROMBOSIS. CONSIDER ADDITIONAL TESTING FOR HEMOSTATIC DISORDERS ASSOCIATED WITH INCREASED THROMBOSIS RISK, IF INDICATED. CONSIDER GENETIC CONSULTATION AND COUNSELING OF POTENTIALLY AFFECTED FAMILY MEMBERS REGARDING LABORATORY TESTING. |
|
|
|
|
|
MOLPATH.MUT |
|
48161-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PROS1 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; PROS; protein S (alpha); protein Sa; PS21; PS22; PS23; PS24; PS25; PSA; Random; THPH5; THPH6; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 48162-2 |
Thymidine |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Thymidine [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/L |
|
|
|
|
|
|
CHEM |
|
48162-2 |
|
|
|
|
Both |
|
|
|
0 |
Thymidine SerPl-sCnc |
|
|
|
N |
|
Chemistry; Deoxythymidine; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.73 |
2.21 |
|
|
|
|
|
|
|
umol/L |
|
|
|
0 |
| 48163-0 |
Cytokeratin 19 |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Cytokeratin 19 [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
|
"CYFRA 21-1 in body fluid are 130 ng/mL" |
|
|
|
|
|
CHEM |
|
48163-0 |
|
|
|
|
Both |
|
|
|
0 |
CK 19 Fld-mCnc |
|
|
|
N |
|
Autoimmune hepatitis; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; CK; CK 19; Cyfra 21-1; Fl; Fld; FLU; Fluid; Keratin 19; Keratin, type I cytoskeletal 19; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 48164-8 |
Enolase.neuron specific |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Enolase.neuron specific [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
"NSE in the body fluid was 123 �µg/L" |
|
|
|
|
|
CHEM |
|
48164-8 |
|
|
|
|
Both |
|
|
|
0 |
NSE Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; ENO2; enolase 2; Fl; Fld; FLU; Fluid; Gamma-enolase; Level; Mass concentration; NSE; Phosphopyruvate dehydratase; Phosphopyruvate hydratase.gamma subunit; Point in time; QNT; Quan; Quant; Quantitative; Random; Spec; Tumor marker |
2.42 |
2.21 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 48165-5 |
Squamous cell carcinoma Ag |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Squamous cell carcinoma Ag [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ug/L |
"The SCCA in the body fluid was 30�µg/L" |
|
|
|
|
|
CHEM |
|
48165-5 |
|
|
|
|
Both |
|
|
|
0 |
SCC Ag Fld-mCnc |
|
|
|
N |
|
Antigen; Antigens; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; SCC; Sq; Squamous cell associated; Tumor marker |
2.7 |
2.21 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
| 48166-3 |
Beta-2-Microglobulin |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Beta-2-Microglobulin [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
g/dL |
"The B2-microglobulin in the body fluid was 4mg/L" |
|
|
|
|
|
CHEM |
|
48166-3 |
|
|
|
|
Both |
|
|
|
0 |
B2 Microglob Fld-mCnc |
|
|
|
N |
|
B; B/F; B2 Microglob; b2-M; BF; bod; Bodies; Body fluid; Body fluid, unsp; Chemistry; Fl; Fld; FLU; Fluid; Hematology; Heme; II; Level; Mass concentration; Microglob; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
2.21 |
|
|
|
|
|
|
|
g/dL |
|
|
|
0 |
| 48167-1 |
Prostate specific Ag/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Prostate specific Ag/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/g creatinine |
"PSA (prostate specific antigen) / creatinine ratio was 3.6" |
|
|
|
|
|
CHEM |
|
48167-1 |
|
|
|
|
Both |
|
|
|
0 |
PSA/Creat Ur |
|
|
|
N |
|
Antigen; Antigens; Chemistry; CR; Crea; Creat; Kallikrein 3; Mass concentration ratio; Mass ratio; MCRto; P-30 antigen; Point in time; PS; PSA; QNT; Quan; Quant; Quantitative; Random; Seminin; Spec; Tumor marker; UA; UCr; UR; Urn |
2.42 |
2.21 |
|
|
|
|
|
|
|
ng/g{creat} |
|
|
|
0 |
| 48168-9 |
5-Hydroxyindoleacetate |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
5-Hydroxyindoleacetate [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
"The 5HIAA in urine was Negative" |
|
|
|
|
|
CHEM |
|
48168-9 |
|
|
|
|
Both |
|
|
|
0 |
5OH-indoleacetate Ur Ql |
|
|
|
N |
|
5HIA; 5HIAA; 5-HIAA; 5-Hydroxy indoleacetate; 5-hydroxyindoleacetic acid; 5OH-indoleacetate; Chemistry; Hydroxyindoacet; Oncology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serotonin metabolite; Tumor marker; UA; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
